Galvokimig not checked
UCB Biopharma SRL · UCB9741
FollowEvery change as it happens, and a Monday email
Trials
3 active
5 in total · 3 in the EU
What this is
- How it works
- An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
- How it’s given
- “Drug: Galvokimig Pharmaceutical form: Solution for injection”In the company’s words, NCT07277660 on ClinicalTrials.gov
- Tested for
- Atopic Dermatitis, Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
- Main trialPhase 2
- “The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).”In the company’s words, NCT07277660 on ClinicalTrials.gov
- Other names
- UCB9741
Other drugs for Atopic Dermatitis
Coming up3
- 17 May 2027Phase 2 trial completes · ClinicalTrials.gov
- 28 Feb 2029Phase 2 trial completes · ClinicalTrials.gov
- 29 Jun 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 17 May 2027 | A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis | |
| Phase 2Recruiting | 28 Feb 2029 | A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis | |
| Phase 2Recruiting | 29 Jun 2029 | A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis | |
| Phase 1/2Completed | 23 Apr 2024 | A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis | |
| Phase 1Completed | 1 Jan 2025 | A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026